<DOC>
	<DOC>NCT01624636</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)</brief_summary>
	<brief_title>Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Active choroidal neovascular AMD in at least one eye. Retinal disease other than AMD that, in the investigator's opinion, would interfere with safety or study conduct. Choroidal neovascularization due to a cause other than AMD. In the study eye, media opacity that, in the investigator's opinion, would interfere with study conduct. Any disease or concomitant (or recent) medication expected to cause systemic immunosuppression. History of meningococcal meningitis in the past 10 years, or any history of recurrent meningitis. History of hospitalization for pneumococcal pneumonia within the past 3 years. History of serious systemic infection within the past 12 months. Any of the following treatments to the study eye within 7 days prior to study drug dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF inhibitor. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Age-related Macular Degeneration</keyword>
	<keyword>Wet AMD</keyword>
	<keyword>Neovascular AMD</keyword>
</DOC>